Furthermore, a meta-analysis of 1605 patients in 11 trials with EGFRwt NSCLC, showed that chemotherapy was superior to EGFR-TKIs, with HR for PFS of 1.84 (95% CI 1.35–2.52) and ORR 16.8 vs. 7.2% [62]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.